ProCE Banner Activity

Analysis: Prognostic Effect of Time From Diagnosis to Treatment in Newly Diagnosed AML

Slideset Download
Conference Coverage
Retrospective analysis of large cohort of registry patients finds that TDT exerts no significant or clinically relevant effects on outcomes following intensive induction treatment with standard-dose cytarabine/daunorubicin (7+3) in newly diagnosed AML.

Released: December 13, 2019

Expiration: December 11, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company